Advertisement

Synthesis and Therapeutic Applications of Oligonucleotides Containing 2′-O,4′-C-Ethylene- and 3′-O,4′-C-Propylene-Bridged Nucleotides

  • Koji Morita
  • Makoto Koizumi
Chapter

Abstract

Recently, bridged nucleic acids have come to be more utilized as one of the promising components of therapeutic oligonucleotides. Oligonucleotides containing 2′-O,4′-C-ethylene-bridged nucleic acid (ENA) have been synthesized as functional oligonucleotides to further optimize the 2′-O,4′-C-methylene-linkage of bridged nucleic acids (2′,4′-BNA) or locked nucleic acids (LNA). Oligonucleotides containing ENA residues show three notable properties: (i) a high affinity to complementary single-stranded RNA to form duplexes, (ii) a triplex formation with double-stranded DNA, and (iii) a dramatically high resistance compared to 2′,4′-BNA/LNA against exonucleases and endonucleases. On the basis of these properties, ENA-modified oligonucleotides are currently being developed as therapeutics of genetic disorders such as Duchenne muscular dystrophy (DMD). On the other hand, a modified nucleotide containing 3′-O,4′-C-propylene linkage can be incorporated into the third position of 2′,5′-oligoadenylate (2-5A) to maintain biological activities with nuclease resistance. This modified 2-5A with 3′-O,4′-C-propylene adenosine could be useful for novel anti-cancer and anti-viral reagents as an RNase L activator.

Keywords

2′-O,4′-C-ethylene-bridged nucleic acid 3′-O,4′-C-propylene-bridged nucleic acid Locked nucleic acids Antisense Triplex-forming oligonucleotides Exon skipping Duchenne muscular dystrophy 2′,5′-oligoadenylate and RNase L 

References

  1. 1.
    Bisbal C, Silverman RH (2007) Diverse functions of RNase L and implications in pathology. Biochimie 89:789–798CrossRefPubMedGoogle Scholar
  2. 2.
    Chakrabarti A, Jha BK, Silverman RH (2011) New insights into the role of RNase L in innate immunity. J.Interferon Cytokine Res 31:49–57CrossRefPubMedGoogle Scholar
  3. 3.
    Koizumi M, Koga R, Hotoda H et al (1997) Biologically active oligodeoxyribonucleotides–IX. Synthesis and anti-HIV-1 activity of hexadeoxyribonucleotides, TGGGAG, bearing 3′- and 5′-end-modification. Bioorg Med Chem 5:2235–2243CrossRefGoogle Scholar
  4. 4.
    Koizumi M, Morita K, Daigo M et al (2003) Triplex formation with 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) having C3′-endo conformation at physiological pH. Nucleic Acids Res 31:3267–3273CrossRefPubMedGoogle Scholar
  5. 5.
    Koizumi M (2007) True antisense oligonucleotides with modified nucleotides restricted in the N-conformation. Curr Top Med Chem 7:661–665CrossRefGoogle Scholar
  6. 6.
    Koshkin AA, Singh SK, Nielsen P et al (1998) LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54:3607CrossRefGoogle Scholar
  7. 7.
    Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628–1644CrossRefGoogle Scholar
  8. 8.
    Lin P, Ganesan A (1998) Solid-phase synthesis of peptidomimetic oligomers with a phosphodiester backbone. Bioorg Med Chem Lett 8:511–514CrossRefGoogle Scholar
  9. 9.
    Morita K, Hasegawa C, Kaneko M et al (2002) 2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett 12:73–76CrossRefGoogle Scholar
  10. 10.
    Morita K, Takagi M, Hasegawa C et al (2003) Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides. Bioorg Med Chem 11:2211–2226CrossRefGoogle Scholar
  11. 11.
    Morita K, Yamate K, Kurakata S et al (2006) Inhibition of VEGF mRNA by 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions. Nucleosides Nucleotides Nucleic Acids 25:503–521CrossRefGoogle Scholar
  12. 12.
    Morita K, Kaneko M, Obika S et al (2007) Biologically stable 2-5A analogues containing 3′-O,4′-C-bridged adenosine as potent RNase L agonists. ChemMedChem 2:1703–1707CrossRefGoogle Scholar
  13. 13.
    Obika S, Nanbu D, Hari Y et al (1997) Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett 38:8735–8738CrossRefGoogle Scholar
  14. 14.
    Obika S, Uneda T, Sugimoto T et al (2001) 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorg Med Chem 9:1001–1011CrossRefGoogle Scholar
  15. 15.
    Player MR, Torrence PF (1998) The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 78:55–113CrossRefGoogle Scholar
  16. 16.
    Rusch L, Zhou A, Silverman RH (2000) Caspase-dependent apoptosis by 2′, 5′-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interf Cytokine Res 20:1091–1100CrossRefGoogle Scholar
  17. 17.
    Surono A, Van Khanh T, Takeshima Y et al (2004) Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum Gene Ther 15:749–757CrossRefGoogle Scholar
  18. 18.
    Takagi M, Yagi M, Ishibashi K et al (2004) Design of 2′-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic Acids Symp Ser 48:297–298CrossRefGoogle Scholar
  19. 19.
    Tnani M, Bayard BA (1998) Lack of 2′,5′-oligoadenylate-dependent RNase expression in the human hepatoma cell line HepG2. Biochim Biophys Acta 1402:139–150CrossRefGoogle Scholar
  20. 20.
    Yagi M, Takeshima Y, Surono A et al (2004) Chimeric RNA and 2′-O, 4′-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA. Oligonucleotides 14:33–40CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Modality Research LaboratoriesDaiichi Sankyo Co., Ltd.TokyoJapan

Personalised recommendations